Latest / The BioHub - by Avetix
Josh Mandel-Brehm - CEO CAMP4 Therapeutics at BIO Boston 2025
Josh Mandel-Brehm, CEO of CAMP4 Therapeutics
In this episode, I sit down with Josh Mandel-Brehm, the CEO of CAMP4 — a company pioneering a completely new approach in RNA therapeutics: upregulating gene expression using antisense oligonucleotides (ASOs).
Josh shares the journey from a 5-person team to a publicly traded company, and how CAMP4’s platform is unlocking treatment for diseases previously out of reach — particularly in rare genetic and CNS disorders.
We dive into:
— What makes CAMP4’s approach so different— How they’ve scaled in a challenging market— The transition from private to…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.